DIR: Trends, Issues, and Impending Impacts
|
|
- Matthew Murphy
- 6 years ago
- Views:
Transcription
1 DIR: Trends, Issues, and Impending Impacts Lari Harding Vice President, Product Marketing Chris Smith, R.Ph Director, Pharmacy Business Intelligence 1
2 Disclosures Lari Harding is the Vice President, Product Marketing with Inmar. The conflict of interest was resolved by peer review of the slide content. Chris Smith is the Director, Pharmacy Business Intelligence with Inmar. The conflict of interest was resolved by peer review of the slide content. Learning Objectives Define how DIR fees are assessed, the current range of clawbacks, industry benchmarks, and mitigation strategies. Execute accounting best practices for predicting DIR and managing cash flow. Evaluate DIR technology tools and service solutions from PSAOs, Central Pay, and Reconciliation providers. 2
3 What are DIR fees? DIR is the abbreviation for Direct and Indirect Remuneration 11 types of DIR Any and all rebates, subsidies, or other price concessions that serve to decrease the costs incurred by the Part D Plan sponsor for a drug Includes discounts, chargebacks or rebates, cash discounts, free goods contingent of a purchase agreement, up-front payments, coupons, goods in kind, free or reduced price services or grants, or other price concessions from all stakeholders What are DIR fees? Reported annually to CMS: PBM Rebates Rebates accrued All other* Rebate admin fees reported as DIR Price concessions for admin services Price concessions from manufacturers Legal settlements Amounts Received from Pharmacies (New as of 6/23/17) Amounts Paid to Pharmacies (New as of 6/23/17) Risk sharing adjustments All other DIR* 3
4 Pharmacies Have Dubbed Them Clawbacks and some other 4 letter words The money is generally recouped Weekly, Quarterly or in Trimesters as a takeback on the 835s in a non-standard way There is usually no reasonable chance to earn the whole fee back No standard set of measures The fee is sometimes charged against products where adherence isn t an opportunity Fee sometimes exceeds dispensing fee, and in some cases the whole revenue collected There is no transparency at the point of sale making it very difficult to run a business Where did DIR come from? Important to understand the process on how Medicare Part D (MPD) plans are built Every year, a plan has to create a bid for a given plan for a particular geographic area The bid contains all information that Center for Medicare and Medicaid Services (CMS) requests in order to award the bid. A bid can contain 2000 pages or more! Certain aspects of the bid are due at different times: Formulary by April 18 Full bid by first Monday in June The bid projects what premiums, copays, risk adjustments, rebates, and the monthly funding needed from the Federal government Reconciliation with CMS by end of June of next calendar year 4
5 Help from CMS??? Source: Final Medicare Part D DIR Reporting Requirements for 2015_1.pdf published May 31, Regular Pharmacy Plan vs MPD plan financials IN OUT IN OUT Employer Premium Overhead Risk Corridor Risk Corridor Overhead Other Providers Tax $ CMS Your Premium DIR Premiums Providers 5
6 Gross DIR Impact DIR STATS Started in 2013 Burst on the scene in 2015 Retrospective, non-standard assessment $50K-$100K/pharmacy at risk Complex formulas and changes every year Some intended to be Quality based and often punitive Average $250 brand claim could be assessed a fee of $7.50 to $13.75 Average pharmacy Gross Profit per Brand Rx is ~$15 DIR Fee is 50 90% of gross profit What is at stake? In an analysis of multiple clients across all industry segments, the average amount of sales subject to DIR was 39.4% of ALL Third Party sales. Low was 31.5%. High was 47.66% By PBM, Prime Therapeutics was the lowest at 5.32% of Sales subject to DIR, and Aetna was the highest at 73.47%. Low: 40.6% High: 91.6% Avg: 73.5% Low: 32.1% High: 51.4% Avg: 39.2% Low: 32.1% High: 51.4% Avg: 21.0% 6
7 Industry Trend: 2015 to % 1.2% 1.23% 1.32% 1.0% 0.88% 0.93% 0.88% 1.00% 0.97% 0.8% 0.78% 0.94% 0.6% 0.60% 0.60% 0.62% 0.61% 0.55% 0.61% 0.58% 0.60% 0.4% 0.25% 0.27% 0.36% 0.2% 0.35% 0.28% 0.31% 0.27% 0.27% 0.26% 0.42% 0.37% 0.45% 0.37% 0.0% Q Q Q Q Q Q Q Q Q Q Service Fees as % of Sales DIR Fees as a % of Sales Let s break it down further According to Inmar data, the average pharmacy does ~60K Rx s per year at $72/Rx. This means the average pharmacy generates $4.32 MM in Sales and $864,000 in profit based on a 20% gross margin. DIR of $43,200 is 1% of Total Sales, but 5% of Total Gross Profit DIR is 2.82% of Part D sales, but 14.8% of Part D Gross Profit 7
8 Metrics are changing the pharmacy business model There are five flavors of value based/quality contracting Pure Incentive Pay In and Earn Back DIR Penalty Scale Modifiers: HRMs are Heavily Weighted Weighted Averages Plus MTM Methods of DIR assessment % of Ingredient Revenue % of AWP Per Rx $ fee (straight or scaled) Rate True-up Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 Trimester 1 Claims Trimester 1 Trimester 1 Collection CAREMARK Trimester 2 Claims Trimester 2 Trimester 2 Collection Trimester 3 Claims Caremark Trimester 3 Caremark Trimester 3 Collection CIGNA Q1 Reported DIR fees collected per claim via 835 files YTD Reported (Q1- Q2) YTD Reported (Q1- Q3) 2017 Reported (Q1- Q4) 2017 DIR Rebate Payment DIR fees collected per claim via 835 files EnvisonRX Q1 Reported Q2 Reported Q3 Reported Q4 Reported Contingent performance fees collected on a per claim basis, via 835 file Optum RX Contingent performance measurements, 2017 calendar year to date Contingent performance fee calculation Fee Reconciliation 8
9 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 ESI Magellan Q1 Reported Measurement Lump Sum DIR Fee Collection DIR fees collected per claim, via 835 file Q2 Reported Measurement Lump Sum DIR Fee Collection Q3 Reported Lump Sum DIR Fee Collection and potential for either Rebate or Additional Collection Measurement Lump Sum DIR Fee Collection Lump Sum DIR Fee Collection Prime Therapeutic Measurement Measurement Lump Sum DIR Fee Collection Lump Sum DIR Fee Collection Measurement Lump Sum DIR Fee Collection DIR Contracts. Quality or $? Type Number of Plans with DIR How have pharmacies reacted? CVS 7 2 Number w Quality as some component Number with Mixed Quality and GDR 9 8 or 10* 5 5 or 7* Walgreens Walmart Rite Aid 0 1 Number with Quality Only 4 3 Kroger 13 9 *Depending on contract From Drug Channels blog. 9
10 What is happening from a policy perspective? 2014 Medicare Part D Call letter and related follow up, finally settled in September of 2014, made effective for CY 2016 attempted to delineate what price concession needed to be reported at point of sale via the PDE and what needed to be reported via the DIR mechanisms. Established the rule that Amounts that cannot be reasonably determined at the Point-of-Sale will be reported as DIR. Final Medicare Part D DIR Reporting Requirements for 2015 published May 31, 2016 established: What was and was not considered DIR (table published earlier) What category the DIR associated with pharmacy needed to be reported to The DIR Storm 10
11 White Papers The Response was Overwhelming 11
12 Legislation H.R "Improving Transparency and Accuracy in Medicare Part D Spending Act" Seeks to prohibit post adjudication DIR Fees. Currently referred to the House Energy and Commerce Subcommittee on Health. H.R "Prescription Drug Transparency Act" Limits PBM power by disallowing PBMs to use PHI to a pharmacy owned by a PBM without the enrollee's permission or incentivizing an enrollee to use pharmacy owned by PBM. Currently referred to the House Energy and Commerce Subcommittee on Health. S. 637 "Creating Transparency to Have Drug Rebates Unlocked Act of 2017" Makes public all rebates, discounts, and price concessions enjoyed by PBMs. Currently referred to the Senate Finance Committee on Health. NCPDP The DIR Task Group under Work Group 45 has: Defined our objective and purpose statement for the DIR task group Defined Types of DIR's seen in the industry today Outlined initial recommendations for Script Level DIR assessments Working on DIR at PLB and PLB with Script ties 12
13 Mitigation Strategies Four ways to gain some control over DIR: Understand your contracts Understand how assessed and when Determine if it is worth it to intervene with patients or on metrics, ID the opportunities, then act! Know your market The Problem with Percent(ile) 82% 70% PDC 80% PDC 90% PDC 82% 70% PDC 90% PDC 80% PDC 13
14 From an Accounting Perspective They are a sales adjustment because the pharmacy agreed to accept a lower reimbursement or revenue amount based on the contract Accruals are important so that you are not surprised by the 3-4 times a year when the takeback surges occur Forecasting is challenging because the comparison points of your peers is not clear, visible and transparent There are tools available to help you plan your finances to appropriately protect yourself from your PSAO, central pay provider, software vendor, and reconciliation providers What You Can Do in Contracting Self Contracting Make financial projections based on your anticipated performance and your contract terms Reconcile DIR claims to your contracts & assess your pharmacy impact Understand the plans, drugs, patients and opportunities for better performance Using a PSAO Have your PSAO share the expected takeback based on contracts Use the data to understand the drugs and the patients so that you can improve Assess your pharmacy impact with your PSAO 14
15 What What You You Can Can Do Do Financially In-House Reconciliation Accrue monthly for the sales adjustments so that you are not overstating sales and profits Report DIR as a sales adjustment, not a business expense or bad debt Build tools to analyze DIR, profitability and ways to improve results Outsourced Reconciliation Participate in Central Pay escrow programs and/or accrue monthly for the sales adjustment Report DIR as a sales adjustment, not a business expense or bad debt Work with your reconciliation provider to continuously improve the toolset available to get insights Evolve to prescriptive and predictive analytics What You Can Do Operationally Participate in pharma and plan funded programs that can improve performance Aggregate and de-identify your data to share your data with CMS Leverage 90 Day Fills, easier to go 4 for 4, than 10 for 12 Med Sync Auto-refill programs Engage on MTM cases & look for vendor support 15
16 Future Implications What if: DIR grew to all Part D plans and MA-PD Plans? $57K More DIR per Pharmacy DIR Expanded to Commercial? At 4% of Ing Rev*=3.9% of Sales or $170K per Pharmacy At 4% of AWP=9.8% of Sales or $423K per Pharmacy At 20% margin, the average pharmacy=$864k in gross profit annually. With the above metrics, DIR would mean an INCREMENTAL $227 to $480K less in gross profit. *Ingredient Revenue = Total Reimbursement minus dispensing fee Questions? 16
DIR FEES: WHAT YOU NEED TO KNOW JULY 13, :00 10:00 AM
DIR FEES: WHAT YOU NEED TO KNOW JULY 13, 2017 9:00 10:00 AM ACPE UAN: 0107-9999-17-078-L04-P 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists: Upon completion of this CPE
More informationHow Medication Adherence and Outcomes Are Changing the Business Model
How Medication Adherence and Outcomes Are Changing the Business Model Laura Cranston Executive Director Todd Sega Manager, Payer Relations Lari Harding VP, Strategy & Growth Healthcare Network 3 Session
More informationUnderstanding Pay For Performance and DIR Impact to Pharmacy Reimbursement
Understanding Pay For and DIR Impact to Pharmacy Reimbursement A Public Service Announcement brought to you by Melanie Maxwell, MHP Vice President RxSelect Pharmacy Services Please Don t Shoot the Messenger
More informationDIR fees are knocking down pharmacy profits
16 America s PHARMACIST November 2016 DIR fees are knocking down pharmacy profits by Bruce A. Semingson, Pharmacist In 2016, retail pharmacy will pay between $360 million and $2.16 billion in direct and
More informationImplement a definition of negotiated price to include all pharmacy price concessions.
NCPA Analysis of Medicare Part D Pharmacy DIR Fee Reform Policy Proposal and Other Policies Impacting Community Pharmacies in the CMS Proposed Rule, Modernizing Part D and Medicare Advantage to Lower Drug
More informationTHANK YOU SPONSORS 2
1 THANK YOU SPONSORS 2 How to: Power Up your pharmacy benefit plan Brent Matthews, Benefits Advisor/Principal, TrueNorth Companies Aaron Viertel, Director of Clinical Management, TrueNorth Companies 3
More informationSurvey Analysis of January 2014 CMS Medicare Part D Proposed Rule
Survey Analysis of January 2014 CMS Medicare Part D Proposed Rule Prepared for: Pharmaceutical Care Management Association Prepared by: Stephen J. Kaczmarek, FSA, MAAA Principal and Consulting Actuary
More informationPresented January 20 th by Pharmacy Healthcare Solu7ons, Inc. Don Dietz, R.Ph, MS, Vice President
Presented January 20 th by Pharmacy Healthcare Solu7ons, Inc. Don Dietz, R.Ph, MS, Vice President Disclosures Don Dietz is an employee of Pharmacy Healthcare Solu0ons, Inc. The conflict of interest was
More informationUnderstanding Pharmacy Benefit Management Services
Understanding Pharmacy Benefit Management Services Peter Cullen VP, Business Development and Strategic Initiatives March 12, 2014 Innovation Session Overview and Learning Objectives Session Overview: Provide
More informationPharmacy Program Management: Pitfalls, Challenges, and Best Practices About Solid Benefit Guidance specialty 60,000,000 covered member lives INSIDER
Pharmacy Program Management: Pitfalls, Challenges, and Best Practices October 2, 2017 This presentation contains proprietary information and is not to be reproduced or further distributed without permission
More informationMEDICARE PLAN PAYMENT GROUP
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 MEDICARE PLAN PAYMENT GROUP Date: June 23, 2017 To: From: All Part
More informationEmployer Group Plans Drive Medicare PDP Growth
Employer Group Plans Drive Medicare PDP Growth 3/8/2013 by Debra A. Donahue Medicare stand-alone prescription drug plans (PDPs) covered almost 22.4 million people as of February 1, 2013 and gained more
More informationTHIRD-PARTY PHARMACY RECONCILIATION
THIRD-PARTY PHARMACY RECONCILIATION Billy Caster Sales Solution Expert Inmar Healthcare Network Jon Brumbaugh Sr. Manager, Product Inmar Healthcare Network Session Description A discussion and presentation
More informationMedicaid Prescribed Drug Program Spending Control Initiatives. For the Quarter April 1, 2014 through June 30, 2014
Medicaid Prescribed Drug Program Spending Control Initiatives For the Quarter April 1, 2014 through June 30, 2014 Report to the Florida Legislature January 2015 Table of Contents Purpose of Report... 1
More informationMedicare Modernization Act (MMA)
Medicare Modernization Act (MMA) Julian Whitekus SEAC Conference Charlotte, N.C. November 16 18, 2005 WHAT IS AT STAKE : Projected U.S. Retail Rx Drug Spending 2005 (Total = $223.5 billion) 2006 (Total
More informationINDUSTRY TRENDS IN PHARMACY REIMBURSEMENT
INDUSTRY TRENDS IN PHARMACY REIMBURSEMENT Heather Shouse, Sr. Director, Healthcare Solutions/ Inmar Jon Brumbaugh, Sr. Manager, Product, Healthcare / Inmar Disclosure We have no relationships with commercial
More informationPayer Channel Forecasting and Analysis. Patrick J. Park, PharmD, MBA Director, Business Decision Support Daiichi Sankyo, Inc.
Payer Channel Forecasting and Analysis Patrick J. Park, PharmD, MBA Director, Business Decision Support Daiichi Sankyo, Inc. Disclaimer The views and opinions expressed in this presentation are those of
More informationImpact of H.R. 1038/S. 413 on CMS Payments Under Part D
At the request of the (NCPA), Wakely Consulting Group, LLC (Wakely) has estimated the financial impact of companion House and Senate bills H.R. 1038/S. 413 ( Improving Transparency and Accuracy in Medicare
More informationThird Quarter 2017 Earnings Conference Call
Third Quarter 2017 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer November 6, 2017 Forward-looking Statements This
More informationPrescription Drug Pricing and Community Pharmacy NALEO Legislative Summit on Health October 21, 2017
Prescription Drug Pricing and Community Pharmacy NALEO Legislative Summit on Health October 21, 2017 Ronna Hauser, PharmD VP Pharmacy Affairs The strength of our numbers NCPA represents America's 22,000+
More informationM and A Activity Shakes Up PDP Leader Board
M and A Activity Shakes Up PDP Leader Board 3/2/2012 by Debra A. Donahue March 8, 2012 Update: The sixth paragraph, fourth sentence in the Business Strategy report was updated to read: Should Express Scripts'
More informationHIPIOWA - IOWA COMPREHENSIVE HEALTH ASSOCIATION Unaudited Balance Sheet As of July 31
Unaudited Balance Sheet As of July 31 Total Enrollment: 407 Assets: Cash $ 9,541,661 $ 1,237,950 Invested Cash 781,689 8,630,624 Premiums Receivable 16,445 299,134 Prepaid 32,930 34,403 Assessments Receivable
More informationHIPIOWA - IOWA COMPREHENSIVE HEALTH ASSOCIATION Unaudited Balance Sheet As of January 31
Unaudited Balance Sheet As of January 31 Total Enrollment: 371 Assets: Cash $ 1,408,868 $ 1,375,117 Invested Cash 4,664,286 4,136,167 Premiums Receivable 94,152 91,261 Prepaid 32,270 33,421 Assessments
More informationDelivering Value for All Health Care Stakeholders. Larry Merlo President & Chief Executive Officer
Delivering Value for All Health Care Stakeholders Larry Merlo President & Chief Executive Officer Agenda Our Value Proposition Has Never Been Stronger We See Compelling Opportunities in a Robust Health
More informationPharmacy Billing and Reimbursement
FSHP Disclosure Pharmacy Billing and Tara L McNulty RPhT, CPhT I, Tara McNulty, do not have a vested interest in or affiliation with any corporate organization offering financial support or grant monies
More informationMEDICARE PART D PRESCRIPTION DRUG EVENTS (PDE) RECONCILIATION
MEDICARE PART D PRESCRIPTION DRUG EVENTS (PDE) RECONCILIATION 2-06-15 Presented by: Alexander Luong, Pharm.D. Candidate 2015 University of the Pacific Preceptor: Dr. Craig Stern, Pharm.D. MBA President,
More informationMedicare Advantage: Early Views and Trend Spotting: What We Know From Analyzing Public Data Files
Medicare Advantage: Early Views and Trend Spotting: What We Know From Analyzing Public Data Files By Marsha Gold, Sc.D. Senior Fellow Mathematica Policy Research Presentation to the Alliance for Health
More informationMEDICARE PLAN PAYMENT GROUP
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 MEDICARE PLAN PAYMENT GROUP Date: May 30, 2018 To: From: All Part D
More informationSession 64PD, Risk-Sharing Arrangements in Medicare Advantage
Session 64PD, Risk-Sharing Arrangements in Medicare Advantage Presenters: Adam J. Barnhart, FSA, MAAA Hillary H. Millican, FSA, MAAA Simon J. Moody, FSA, MAAA SOA Antitrust Disclaimer SOA Presentation
More informationWashington State Health Insurance Pool Treasurer s Report January 2017 Financial Review
Washington State Health Insurance Pool Treasurer s Report January 2017 Financial Review 1. 2016 Interim III Assessment Required An assessment of $8.5 M is required to adequately fund the pool until the
More informationPay for Performance & the Changing Landscape for Pharmacy: A Panel Discussion
Pay for Performance & the Changing Landscape for Pharmacy: A Panel Discussion Panelists: Mark Conklin, Pharmacy Quality Solutions Alex Cruz, Healthfirst Crystal Lennartz, Health Mart Jesse McCullough,
More informationSpecialty Pharmacy Trends: Payer and Industry Considerations for Specialty Pharmacies
Specialty Pharmacy Trends: Payer and Industry Considerations for Specialty Pharmacies September 18, 2017 Washington, DC Frier & Levitt, LLC Jonathan E. Levitt, JD Co-Founding Partner jlevitt@frierlevitt.com
More informationWashington State Health Insurance Pool Treasurer s Report August 2017 Financial Review
Washington State Health Insurance Pool Treasurer s Report August 2017 Financial Review 1. 2017 Interim I Assessment Required An assessment of $9.5 M was required to adequately fund the pool until the next
More informationModeling Price Increases and the Effects on Customer Segments
Modeling Price Increases and the Effects on Customer Segments CBI Medicaid Congress May 9, 2017 Jennifer English Director, Pricing, Contracting and Govt Programs, Insmed, Inc. Disclaimer The opinions and
More informationWashington State Health Insurance Pool Treasurer s Report December 2017 Financial Review
Washington State Health Insurance Pool Treasurer s Report December 2017 Financial Review 1. 2017 Interim III Assessment Required An assessment of $8.5 M is required to adequately fund the pool until the
More informationAnatomy Of A Rate. Presented By: Anjanette Simone Vice President, Aon.
2017 HR FLORIDA Anatomy Of A Rate Presented By: Anjanette Simone Vice President, Aon Agenda Underwriting / Rating Overview Funding Arrangement Options Incurred vs. Mature Claims Underwriting Basics & Components
More informationUnique PBM Capabilities
Gaining Lives With Our Unique PBM Capabilities Jon Roberts Executive Vice President & President, CVS/caremark Agenda Performance Highlights Pharmacy Trends and Cost Management Programs Well Positioned
More informationEligibility and Enrollment in the Medicare Prescription Drug Program
Eligibility and Enrollment in the Medicare Prescription Drug Program Danielle Moon, Centers for Medicare and Medicaid Services Linda A. Malek, Esq., Partner Moses & Singer LLP Medicare Prescription Drug
More informationThe Declining Value of Payer Access: Defining and improving Rebate Efficiency in the current healthcare landscape
The Declining Value of Payer Access: Defining and improving Rebate Efficiency in the current healthcare landscape Lucas Greenwalt, Senior Principal Amundsen Consulting Prepared for: CBI Gross to Net Boot
More informationPart D: The New Medicare Prescription Drug Law Implications for Medicaid
Part D: The New Medicare Prescription Drug Law Implications for Medicaid Vernon K. Smith, Ph.D. HEALTH MANAGEMENT ASSOCIATES For State Coverage Initiatives National Meeting Washington, D.C. February 4,
More informationPrescription Drug Rebates and Part D Drug Costs
Prescription Drug Rebates and Part D Drug Costs Analysis of historical Medicare Part D drug prices and manufacturer rebates Prepared for: America s Health Insurance Plans Prepared by: Nicholas J. Johnson,
More informationFourth Quarter 2016 Earnings Conference Call
Fourth Quarter 2016 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer February 9, 2017 Revised 2/9 Forward-looking
More informationWhat to Expect for Pharmacy Benefits and Drug Cost Trends for 2018 & 2019
What to Expect for Pharmacy Benefits and Drug Cost Trends for 2018 & 2019 Mid-Sized Retirement and Healthcare Plan Management Conference 2018. Innovative Rx Strategies, LLC. All rights reserved. The Ever
More informationWashington State Health Insurance Pool Treasurer s Report February 2018 Financial Review
Washington State Health Insurance Pool Treasurer s Report February 2018 Financial Review 1. 2017 Interim III Assessment Required An assessment of $8.5 M was required to adequately fund the pool until the
More informationWashington State Health Insurance Pool Treasurer s Report January 2018 Financial Review
Washington State Health Insurance Pool Treasurer s Report January 2018 Financial Review 1. 2017 Interim III Assessment Required An assessment of $8.5 M was required to adequately fund the pool until the
More informationWashington State Health Insurance Pool Treasurer s Report September 2018 Financial Review
Washington State Health Insurance Pool Treasurer s Report September 2018 Financial Review 1. 2018 Interim III Assessment Required An assessment of $8.5 M was required to adequately fund the pool until
More informationWashington State Health Insurance Pool Treasurer s Report March 2018 Financial Review
Washington State Health Insurance Pool Treasurer s Report March 2018 Financial Review 1. 2017 Interim III Assessment Required An assessment of $8.5 M was required to adequately fund the pool until the
More informationWashington State Health Insurance Pool Treasurer s Report April 2018 Financial Review
Washington State Health Insurance Pool Treasurer s Report April 2018 Financial Review 1. 2018 Interim I Assessment Required An assessment of $7.0 M is required to adequately fund the pool until the next
More informationSAVINGS GENERATED BY PHARMACY BENEFIT MANAGERS IN THE MEDICARE PART D PROGRAM
February 6, 2014 GLENN GIESE KELLY BACKES SAVINGS GENERATED BY PHARMACY BENEFIT MANAGERS IN THE MEDICARE PART D PROGRAM June 26, 2017 GLENN GIESE RANDALL FITZPATRICK KEVIN MEYER CONTENTS Findings... 1
More informationFourth Quarter 2017 Earnings Conference Call
Fourth Quarter 2017 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer February 8, 2018 Important Information No Offer
More informationProvider Reimbursement Strategies & Opportunities Board of Trustees Meeting
Provider Reimbursement Strategies & Opportunities Board of Trustees Meeting February 5, 2016 Presentation Overview Financing the Health Benefit & Bending the Cost Curve Methods to Address the Triple Aim/SHP
More informationThe Real Deal About Real-Time Benefits. Proven Savings with Up-to-the-Minute, Member-Specific Information Across Multiple Points of Care
The Real Deal About Real-Time Benefits Proven Savings with Up-to-the-Minute, Member-Specific Information Across Multiple Points of Care Cost is a key issue for plan members and a common barrier to medication
More informationNR614: Foundations of Health Care Economics, Accounting and Financial Management
NR614: Foundations of Health Care Economics, Accounting and Financial Management WEEK 7: Budgeting SLIDE 1: Week 7: Week Seven Sample Problem: Budgeting... There is one sample problem provided in week
More informationIMPROVING THE FINANCIAL HEALTH OF YOUR PRACTICE. D e b b i e R i c c i a n d D o n n a R u s s o
IMPROVING THE FINANCIAL HEALTH OF YOUR PRACTICE D e b b i e R i c c i a n d D o n n a R u s s o Please silence or turn off all electronic devices at this time. THANK YOU Agenda Key Performance Indicators
More informationFinancial Statements. Kit Carson County Health Service District. October 2018
Financial Statements Kit Carson County Health Service District Kit Carson County Health Service District Rooted in excellence. Growing in trust. FINANCIAL STATEMENT SUMMARY Income Statement Summary Kit
More informationNational Conference of State Legislatures Impact of Medicare Modernization and New Accounting Rules on States as Employers and Plan Sponsors
December 8, 2004 National Conference of State Legislatures Impact of Medicare Modernization and New Accounting Rules on States as Employers and Plan Sponsors Derek N. Guyton, FSA, MAAA Chicago, Illinois
More informationFourth Quarter 2018 Earnings Conference Call
Fourth Quarter 2018 Earnings Conference Call Larry Merlo President & Chief Executive Officer Eva Boratto Executive Vice President & Chief Financial Officer February 20, 2019 Cautionary Statement Regarding
More informationTHIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE
THIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE Donna Lee Yesner Morgan Lewis and Bockius Phone : 202.739.5887 Email: dyesner@morganlewis.com www.morganlewis.com BACKGROUND In
More informationMarc Claussen, Chiesi USA, Director, Market Access. Donna White, Chiesi USA, Sr. Director, Contracting and Compliance
Marc Claussen, Chiesi USA, Director, Market Access Donna White, Chiesi USA, Sr. Director, Contracting and Compliance The views/observations expressed in this presentation are the personal views/observations
More informationCMS Releases Proposed Rule on Medicare Advantage and Medicare Prescription Drug Plan MLR Requirements. Jacinta L. Alves
CMS Releases Proposed Rule on Medicare Advantage and Medicare Prescription Drug Plan MLR Requirements Jacinta L. Alves Background: What is an MLR?» MLR stands for Medical Loss Ratio.» An MLR is expressed
More informationMedicare Part D: Retiree Drug Subsidy
A D V I S O R Y S E R V I C E S Medicare Part D: Retiree Drug Subsidy Programs to Control Fraud, Waste, and Abuse September, 2006 K P M G L L P Overview Summary Medicare Part D Prescription Drug Program
More informationMedicaid Prescribed Drug Program. Spending Control Initiatives
Medicaid Prescribed Drug Program Spending Control Initiatives For Quarters Ended September 30, December 31, Table of Contents Purpose of Report... 1 Executive Summary... 2 Pharmacy Appropriations and Spending
More informationTITLE 42 - THE PUBLIC HEALTH AND WELFARE CHAPTER 7 - SOCIAL SECURITY SUBCHAPTER XVIII - HEALTH INSURANCE FOR AGED AND DISABLED
TITLE 42 - THE PUBLIC HEALTH AND WELFARE CHAPTER 7 - SOCIAL SECURITY SUBCHAPTER XVIII - HEALTH INSURANCE FOR AGED AND DISABLED Part D - Voluntary Prescription Drug Benefit Program subpart 2 - prescription
More informationUnderstanding the Bidding Process
Medicare Prescription Drug, Modernization and Improvement Act ( MMA ) Understanding the Bidding Process Presented by William E. Gramlich, Esquire One Logan Square Philadelphia, PA 19103 215-569 569-57395739
More informationMedicaid Prescription Drug Payment Reform
Medicaid Prescription Drug Payment Reform Spring 2006 NCSL Health Chairs Meeting John M. Coster, Ph.D., R.Ph. June 10, 2006 1 Community Retail Pharmacy In 2005, there were approximately 56,000 community
More informationMedicare Modernization Act and Medicare Part D: Status of Implementation
Medicare Modernization Act and Medicare Part D: Status of Implementation November 1, 2005 John Richardson Avalere Health LLC Avalere Health LLC The intersection of business strategy and public policy What
More informationI. PURPOSE. A. The primary objectives of Molina Healthcare s Transition Policy and Procedure are:
I. PURPOSE The purpose of the Policy and Procedure is to ensure necessary continuity of treatment and to provide adequate time and transition process to introduce the enrollee and their prescribing physician
More informationBrian Bertha VP, Corporate Strategy and Business Development McKesson U.S. Pharmaceutical
Brian Bertha VP, Corporate Strategy and Business Development McKesson U.S. Pharmaceutical 2 Safe Harbor Clause Some of the information in this presentation may constitute forwardlooking statements that
More informationMEDICARE PART D POLICY FORMULARY: TRANSITION PROCESS Policy Number: 6-C
MEDICARE PART D POLICY FORMULARY: TRANSITION PROCESS Policy Number: 6-C Coverage Statement This Policy is applicable to: Medco PDP, Beneficiaries, Enhanced PDPs, Client PDPs and Client MA-PDs, to the extent
More informationCo-pay Card Program Monitoring and Optimization November 2014
Primary/Final Payer Analysis Co-pay Card Program Monitoring and Optimization November 2014 Symphony Health Solutions offers an array of Managed Markets Studies CONSULTING/ANALYTICAL STUDIES Managed Markets
More informationProvisions of the Medicare Modernization Act
Provisions of the Medicare Modernization Act Medicare Prescription Drug Modernization and Improvement Act of 2003 (MMA) Todd Whitney, FSA, MAAA Wakely Consulting Group Highlights of New Act New Rx Benefit
More informationSan Francisco Health Service System Health Service Board
San Francisco Health Service System Health Service Board HSS Rates & Benefits Committee Meeting City Plan (UHC) Employer Group Waiver Plan (EGWP) + Wrap Presentation April 12, 2012 Prepared by Aon Hewitt
More informationFactor Leave Accruals. Accruing Vacation and Sick Leave
Factor Leave Accruals Accruing Vacation and Sick Leave Factor Leave Accruals As part of the transition of non-exempt employees to biweekly pay, the UC Office of the President also requires standardization
More informationSpecialty Pharmacy: A Key to Organizational Success in Population Health Management
Specialty Pharmacy: A Key to Organizational Success in Population Health Management Scott Knoer, MS, PharmD, FASHP Chief Pharmacy Officer, Cleveland Clinic Steve Rough, MS, RPh, FASHP Director of Pharmacy,
More informationThe Impact of the Medicare Prescription Drug Legislation on Pharmaceutical Revenues
The Impact of the Medicare Prescription Drug Legislation on Pharmaceutical Revenues Presented By: Jack Rodgers PricewaterhouseCoopers February 27, 2004 P w C Overview of Recent Medicare Act On December
More informationRegional Training. PACE Prescription Drug Event Data Training. August 17, 2005 Baltimore, MD I-1
PACE Prescription Drug Event Data August 17, 2005 Baltimore, MD I-1 Introduction Presented by: Aspen Systems Corporation PACE Prescription Drug Event Data I-2 Purpose To provide participants with the support
More information2018 Medicare Part D Transition Policy
Regulation/ Requirements Purpose Scope Policy 2018 Medicare Part D Transition Policy 42 CFR 423.120(b)(3) 42 CFR 423.154(a)(1)(i) 42 CFR 423.578(b) Medicare Prescription Drug Benefit Manual, Chapter 6,
More informationSpheria Australian Smaller Companies Fund
29-Jun-18 $ 2.7686 $ 2.7603 $ 2.7520 28-Jun-18 $ 2.7764 $ 2.7681 $ 2.7598 27-Jun-18 $ 2.7804 $ 2.7721 $ 2.7638 26-Jun-18 $ 2.7857 $ 2.7774 $ 2.7690 25-Jun-18 $ 2.7931 $ 2.7848 $ 2.7764 22-Jun-18 $ 2.7771
More informationAppendix I: Data Sources and Analyses. Appendix II: Pharmacy Benefit Management Tools
Appendix I: Data Sources and Analyses This brief includes findings from analyses of the Centers for Medicare & Medicaid Services (CMS) State Drug Utilization Data 1 and CMS 64 reports for federal fiscal
More informationPolicy Evaluation: HB 2126 Oregon Health Plan Preferred Drug List Enforcement and Voluntary Mental Health Preferred Drug List
Drug Use Research & Management Program DHS Division of Medical Assistance Programs, 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: HB 2126 Oregon
More informationMoving From PBM to PBA Model
Moving From PBM to PBA Model Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Pro Pharma Pharmaceutical Consultants, Inc. Under the preceptorship of Dr. Craig Stern
More informationMeeting the Health Care Challenges of Tomorrow. Jon Roberts Executive Vice President & President, CVS Caremark
Meeting the Health Care Challenges of Tomorrow Jon Roberts Executive Vice President & President, CVS Caremark Agenda PBMs: Needed Now More Than Ever Performance Highlights How We Address Payors #1 Priority:
More informationSteve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration
Medicaid Drug Rebates Steve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration Medicaid Drug Rebates History of Medicaid Drug Rebates and Preferred Drug Lists Affordable
More informationPACE & Medicare Part D
PACE & Medicare Part D www.npaonline.org Shawn Bloom National PACE Association Shawnb@npaonline.org (703) 535-1518 PACE & Part D Session Objectives PACE Medication Regulations What Does Part D Cover What
More informationPart II: Medicare Part C and Part D
Part II: Medicare Part C and Part D Part II: Part C and Part D Part C (Medicare Advantage)... 1 Enhanced Payments to Plans for Certain Beneficiary Types... 1 Special Needs Plans: Enrollment of Medicare
More informationSTAR RATINGS PBM PARTNERSHIP, MAXIMUM RESULTS. Michelle Juhanson, CHC, CHPC Director of Compliance and Quality PerformRx
STAR RATINGS PBM PARTNERSHIP, MAXIMUM RESULTS Michelle Juhanson, CHC, CHPC Director of Compliance and Quality PerformRx Agenda History & Timeline Quality Bonus Payment CMS Changes The PBM Role Best Practices
More information2019 Transition Policy
2019 Number: 5.8 Prescription Drug Replaces: 5.8 v.2018 Cross 5.1.2 Transition Fill Monitoring Procedure References: Purpose: To provide guidance on the transition process for new or current Plan members
More informationStep 3: To assist us in determining the available list of pharmacy plans to be contracted, please complete the enclosed Insurance Payer List.
BillingScripts Rx Initial Enrollment Packet Thank you for choosing BillingScripts Rx for your pharmaceutical billing and funding services. This Initial Enrollment Packet contains instructions and forms
More informationXML Publisher Balance Sheet Vision Operations (USA) Feb-02
Page:1 Apr-01 May-01 Jun-01 Jul-01 ASSETS Current Assets Cash and Short Term Investments 15,862,304 51,998,607 9,198,226 Accounts Receivable - Net of Allowance 2,560,786
More informationPre-Existing Condition Insurance Plan Washington State (PCIP-WA) June 2013 Financial Review
Pre-Existing Condition Insurance Plan Washington State (PCIP-WA) June 2013 Financial Review 1. Financial Statements June 2013 U Sheet Due to the timing of the HHS reimbursement receipts, there is no available
More informationFiscal Year 2018 Project 1 Annual Budget
Fiscal Year 2018 Project 1 Annual Budget Table of Contents Table Page Summary 3 Summary of Costs Table 1 4 Treasury Related Expenses Table 2 5 Summary of Full Time Equivalent Table 3 6 Positions Cost-to-Cash
More informationProCare Rx - History ProCare Rx founded as a Healthcare Information Technology Company
ProCare Rx - History 1988 ProCare Rx founded as a Healthcare Information Technology Company 1996 Pharmacy Internet Switching Released 2003 ProCare Pharmacy Care Mail Order & Specialty Pharmacy Established
More informationStrategic Benefits Consulting Services Contract. Administrative Committee Cheryl D. Orr, Vice President of Human Capital August 14, 2018
Strategic Benefits Consulting Services Contract Administrative Committee Cheryl D. Orr, Vice President of Human Capital August 14, 2018 0 DART s Vision for Healthcare Benefits To create a sustainable benefits
More informationMedicare Part D Transition Policy CY 2018 HCSC Medicare Part D
Contract: H0107, H0927, H1666, H3251, H3822, H3979, H8133, H8634, H8554, S5715 Policy Name: Medicare Formulary Transition Purpose: This procedure describes the standard process Health Care Service Corporation
More informationPoint of Service Collections
The Front-End Revenue Cycle Specialists Point of Service Collections Paul Shorrosh, MSW, MBA, CHAM CEO & Founder, AccuReg POS Collections What are we trying to do? Customers want three things: Product
More informationPre-Existing Condition Insurance Plan Washington State (PCIP-WA) November 2014 Financial Review
Pre-Existing Condition Insurance Plan Washington State (PCIP-WA) November 2014 Financial Review 1. Financial Statements November 2014 U Sheet Due to the timing of the HHS reimbursement receipts, there
More informationAutomating Specialty Pharmacy: Identifying Gaps
Automating Specialty Pharmacy: Identifying Gaps Kevin James, R.Ph., MBA VP, Payer Strategy US Bioservices Jeff Spafford President and CEO AssistRx Tony Schueth, M.S. CEO & Managing Partner Point-of-Care
More information2015 PacificSource Medicare Part D Transition Process for contracts H3864 & H4754:
2015 PacificSource Medicare Part D Transition Process for contracts H3864 & H4754: Essentials Rx 6 (HMO), Essentials Rx 14 (HMO), Essentials Rx 15 (HMO), Essentials Rx 16 (HMO), Essentials Rx 19 (HMO),
More informationInsights into pharmacy benefit management, drug trend and the future
Insights into pharmacy benefit management, drug trend and the future 1 Where does your health care dollar go? 2 Pharmacy share of total health spend 25% 21% 20% 19% 15% 10% 10% 5% 0% Retail Drugs as a
More information2012 Checklist for Community Pharmacy. Medicare Part D-Related Information
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2012 Checklist for Community Pharmacy Medicare Part D-Related Information Medicare Part D Valid Prescriber Identifiers For 2012, CMS will continue to permit the
More information